BD Reaches Major Milestone for Rotarex™ Catheter System with First Patient Enrolled in XTRACT™ Registry to Advance Real-World Evidence in Peripheral Artery Disease

FRANKLIN LAKES, N.J. — Oct. 09, 2025 — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACT™ Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex™ Catheter System in the treatment of patients with peripheral artery disease (PAD) lesions.Continue reading

Taiwan AI Smart Health Showcase Center Established at Phoenix Bioscience Core

PHOENIX, Ariz. – To advance health care and biomedical opportunities between Arizona and Taiwan, the City of Phoenix, Arizona Commerce Authority, Arizona State University (ASU), and Taiwan Digital Health Industry Development Association signed a Declaration of Collaboration focused on establishing and promoting the Taiwan AI Smart Health Showcase Center on the Phoenix Bioscience Core (PBC) in downtown. The signing ceremony was held on Oct. 9 at Venture Cafe Phoenix in the 850 PBC Building, 850 N. 5th St​.Continue reading

New Online Resource Spotlights Life Science Investments in Arizona and Across the U.S.

We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $425 billion being invested to drive new R&D, expand manufacturing and create jobs nationwide. The continually updated database is accessible below through a state map of announcements that mention specific cities or states and also a tracker of every public commitment since January 2025.Continue reading

NuvOx and FYR Bio Announce NCI Funding for Liquid Biopsy Collaboration Supporting NuvOx’s Phase IIb Glioblastoma Trial

Tucson, AZ – September 26, 2025 – NuvOx Therapeutics, Inc. (“NuvOx”) and FYR Bio (“FYR”) today announced a collaboration pairing NuvOx’s Phase IIb glioblastoma trial of NanO₂ with FYR’s EV-based liquid-biopsy expertise to provide additional biomarker insights that support clinical development, through an NCI (a division of NIH) grant “Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic”.Continue reading

CND Life Sciences is Granted FDA Breakthrough Device Designation for Its Skin Biopsy-Based Syn-One Test®

SCOTTSDALE, AZ, October 7, 2025 – CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for the company’s Syn-One Test® for aiding the diagnosis of synucleinopathies in patients aged 40 years and older with neurologic conditions that present with clinical features suggestive of a synucleinopathy.

Continue reading

The Journey of a Plasma Donation

Plasma Donors hold the missing puzzle piece for those who rely on plasma-derived therapies.

October is Plasma Awareness Month, an opportunity for CSL to raise awareness about the importance and need for plasma donations to manufacture life-saving therapies.Continue reading